Loading company
Q/C Technologies, Inc.
QCLS · Nasdaq · ·
$0.91+11.0%Sep 29 close
- 1M
- -56.6%
- 6M
- -73.3%
- 1Y
- -78.4%
- 5Y
- -100.0%
QCLS · Nasdaq · ·
$0.91+11.0%Sep 29 close
The quarter ending June 30, 2020, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2020 | 3 months toJun 30, 2019 | Change |
|---|---|---|---|
| Total Revenue | -$1.9K | $464.5K | -100.41% |
| Profit | -$6.6M | -$1.8M | -268.35% |
| Profit per share | -$0.79 | -$0.36 | -119.44% |
| Free Cash Flow | -$2.6M | -$1.4M | -82.89% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Q/C Technologies, Inc. has no earnings call transcript available.
Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbio.com
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Q/C Technologies, Inc.’s Item 2.02 8-K filed November 15, 2018; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.